vs
Side-by-side financial comparison of Employers Holdings, Inc. (EIG) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Employers Holdings, Inc. is the larger business by last-quarter revenue ($170.5M vs $92.9M, roughly 1.8× Vericel Corp). On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -21.3%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -11.4%).
Employers Holdings, Inc. is a U.S.-headquartered insurance holding company that specializes in offering workers' compensation insurance and customized risk management services primarily for small and medium-sized enterprises across the United States. It mainly serves clients in low-to-medium hazard industries, helping them mitigate workplace safety risks and meet relevant regulatory requirements for employee protection.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
EIG vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $170.5M | $92.9M |
| Net Profit | — | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | — | 25.0% |
| Revenue YoY | -21.3% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | — | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $170.5M | — | ||
| Q4 25 | $188.5M | $92.9M | ||
| Q3 25 | $239.3M | $67.5M | ||
| Q2 25 | $246.3M | $63.2M | ||
| Q1 25 | $202.6M | $52.6M | ||
| Q4 24 | $216.6M | $75.4M | ||
| Q3 24 | $224.0M | $57.9M | ||
| Q2 24 | $217.0M | $52.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $23.2M | ||
| Q3 25 | $-8.3M | $5.1M | ||
| Q2 25 | $29.7M | $-553.0K | ||
| Q1 25 | $12.8M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $30.3M | $-901.0K | ||
| Q2 24 | $31.7M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 24.1% | ||
| Q3 25 | -4.7% | 5.1% | ||
| Q2 25 | 15.0% | -3.2% | ||
| Q1 25 | 7.8% | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | 16.4% | -4.3% | ||
| Q2 24 | 18.4% | -11.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 25.0% | ||
| Q3 25 | -3.5% | 7.5% | ||
| Q2 25 | 12.1% | -0.9% | ||
| Q1 25 | 6.3% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 13.5% | -1.6% | ||
| Q2 24 | 14.6% | -8.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.93 | $0.46 | ||
| Q3 25 | $-0.36 | $0.10 | ||
| Q2 25 | $1.23 | $-0.01 | ||
| Q1 25 | $0.52 | $-0.23 | ||
| Q4 24 | $1.14 | $0.40 | ||
| Q3 24 | $1.21 | $-0.02 | ||
| Q2 24 | $1.25 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $169.9M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $955.7M | $354.6M |
| Total Assets | $3.4B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $169.9M | — | ||
| Q4 25 | $169.9M | $137.5M | ||
| Q3 25 | $172.4M | $135.4M | ||
| Q2 25 | $78.1M | $116.9M | ||
| Q1 25 | $100.4M | $112.9M | ||
| Q4 24 | $68.4M | $116.2M | ||
| Q3 24 | $173.9M | $101.7M | ||
| Q2 24 | $126.4M | $102.5M |
| Q1 26 | — | — | ||
| Q4 25 | $19.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $955.7M | — | ||
| Q4 25 | $955.7M | $354.6M | ||
| Q3 25 | $1.0B | $321.9M | ||
| Q2 25 | $1.1B | $306.8M | ||
| Q1 25 | $1.1B | $295.5M | ||
| Q4 24 | $1.1B | $292.0M | ||
| Q3 24 | $1.1B | $257.5M | ||
| Q2 24 | $1.0B | $243.0M |
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.4B | $488.0M | ||
| Q3 25 | $3.5B | $453.3M | ||
| Q2 25 | $3.5B | $435.6M | ||
| Q1 25 | $3.6B | $424.6M | ||
| Q4 24 | $3.5B | $432.7M | ||
| Q3 24 | $3.6B | $390.4M | ||
| Q2 24 | $3.5B | $376.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.02× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $44.7M | $15.0M | ||
| Q3 25 | $29.4M | $22.1M | ||
| Q2 25 | $0 | $8.2M | ||
| Q1 25 | $14.6M | $6.6M | ||
| Q4 24 | $76.4M | $22.2M | ||
| Q3 24 | $51.0M | $10.2M | ||
| Q2 24 | $11.7M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $44.6M | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | $76.3M | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | 35.2% | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | 0.0% | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 1.68× | — | ||
| Q2 24 | 0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EIG
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
